Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 332 for:    prostate cancer AND MRI | ( Map: United States )

PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03232164
Recruitment Status : Recruiting
First Posted : July 27, 2017
Last Update Posted : August 22, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Wisconsin, Madison

Tracking Information
First Submitted Date  ICMJE July 17, 2017
First Posted Date  ICMJE July 27, 2017
Last Update Posted Date August 22, 2019
Actual Study Start Date  ICMJE February 2, 2017
Estimated Primary Completion Date July 31, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 24, 2017)
  • 18F-DCFPyL PSMA-based PET and multi-parametric MRI with DWI for sub-study #1: Primary Prostate Cancer [ Time Frame: Up to 12 months ]
    To evaluate the performance of 18F-DCFPyL PSMA-based PET and multi-parametric MRI (MP-MRI) with DWI (Diffusion Weighted Imaging) and gadolinium DCE (Dynamic Contrast Enhanced) using a dedicated PET/MRI scanner to detect clinically significant larger volume high-grade primary prostate cancer based on prostatectomy step-section pathology correlation.
  • Evaluate 18F-DCFPyL PSMA-based PET for localization for sub-study #2: Biochemical Recurrence [ Time Frame: Up to 12 months ]
    To evaluate the performance of 18F-DCFPyL PSMA-based PET for localization of the site of recurrent prostate cancer in men with biochemical recurrence after definitive prostatectomy with planned salvage external-beam radiation therapy (EBRT). PSA response to prostatic fossa salvage irradiation will be compared with pre-salvage 18F-DCFPyL PET uptake in the radiation field.
  • Compare detectability of 18F-DCFPyL for sub-study #3: Metastatic Androgen-Resistant Prostate Cancer [ Time Frame: Up to 12 months ]
    To compare the detectability of metastatic prostate cancer using 18F-DCFPyL PET obtained from PET/CT and PET/MRI compared to conventional imaging modalities (CIM) (bone scan and CT) in men with androgen-resistant prostate cancer.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03232164 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 24, 2017)
  • Sub-study #1: Detection of local-nodal and distant metastatic disease (PET [ Time Frame: Up to 12 months ]
    Evaluate the performance of 18F-DCFPyL PET and MRI whole body DWI for detection of local-nodal and distant metastatic disease on initial staging compared to conventional imaging modalities (CT and bone scintigraphy).
  • Sub-study #1: Correlation of 18F-DCFPyL PET and MRI [ Time Frame: Up to 12 months ]
    Correlate 18F-DCFPyL PET standardized-uptake values (SUV) and MRI parameters with PSMA expression by prostatectomy pathology IHC.
  • Sub-study #1: Specificity of 18F-DCFPyL [ Time Frame: Up to 12 months ]
    Evaluate the specificity of 18F-DCFPyL PET for differentiating primary prostate cancer versus non-malignant prostate lesions (BPH, prostatitis).
  • Sub-study #1: Low-dose CT versus MRI derived PET SUV [ Time Frame: Up to 12 months ]
    Comparison of whole body low-dose CT and whole body MRI derived PET SUV-quantitation.
  • Sub-study #2: Detection of local-nodal and distant metastatic disease (pelvic) [ Time Frame: Up to 12 months ]
    Comparison of whole body 18F-DCFPyL PET with pelvic MR-MRI and whole body DWI for detection of local-nodal and distant metastatic disease on initial staging compared to conventional imaging modalities (CT and bone scintigraphy).
  • Sub-study #2: Dedicated pelvic 18F-DCFPyL PET/MRI with dynamic PET acquisition and multi-parametric MRI [ Time Frame: Up to 12 months ]
    Evaluate the performance of dedicated pelvic 18F-DCFPyL PET/MRI with dynamic PET acquisition and multi-parametric MRI for differentiation of urine versus recurrent malignancy in the prostatectomy bed.
  • Sub-study #3: Contribution of whole body MRI DWI [ Time Frame: Up to 12 months ]
    Evaluate the contribution of whole body MRI DWI obtained from PET/MRI to improve the diagnostic performance of 18F-DCFPyL PET/CT and PET/MRI for metastatic prostate cancer lesion detection.
  • Sub-study #3: Quantitative accuracy [ Time Frame: Up to 12 months ]
    Assess the quantitative accuracy of 18F-DCFPyL PET standardized uptake value parameters from PET/MRI versus PET/CT.
  • Sub-study #3: Quantitative reproducibility [ Time Frame: Up to 12 months ]
    Assess the quantitative reproducibility of 18F-DCFPyL PET/CT derived-SUV values in normal organ and metastatic tumor lesions.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
Official Title  ICMJE PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
Brief Summary The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence. Development of such a biomarker may be useful to differentiate indolent from aggressive prostate cancer phenotypes allowing for selection of an appropriate risk adaptive therapy.
Detailed Description The investigators will evaluate a novel second-generation low-molecular-weight prostate specific membrane antigen (PSMA)-based positron emission tomography (PET) agent, 18F-DCFPyL, for detection of primary and metastatic prostate cancer. 18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI). The investigators propose to evaluate this PET agent for three different prostate cancer clinical scenarios: (1) detection of clinically significant high-grade prostate cancer and initial staging, (2) detection of sites of recurrence in the setting of biochemical recurrence after definitive prostatectomy, and (3) detection of advanced androgen-resistant metastatic prostate cancer.
Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Intervention Model Description:
Single center, open label, single-arm, pilot study
Masking: None (Open Label)
Primary Purpose: Diagnostic
Condition  ICMJE
  • Prostate Cancer
  • Prostate Neoplasm
Intervention  ICMJE Drug: 18F-DCFPyL PET
18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
Study Arms  ICMJE Experimental: 18F-DCFPyL PET
We will have three separate sub-studies evaluating 18F-DCFPyL PET imaging of prostate cancer in three prostate cancer clinical scenarios under the following subheadings: (1) primary prostate cancer, (2) biochemical recurrence post-prostatectomy prior to radiation therapy, and (3) androgen-resistant metastatic disease.
Intervention: Drug: 18F-DCFPyL PET
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 24, 2017)
36
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 31, 2020
Estimated Primary Completion Date July 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Prostate cancer pathologically proven by prostate biopsy (newly diagnosed for sub-study #1)
  • Prostate biopsy histology grade ≥ Gleason 6, positive biopsy >2 cores.
  • PSA > 0.2 ng/mL for Sub-study #2 or >1.0 ng/mL for Sub-study #3
  • Patients considered as candidates for and medically fit to undergo prostatectomy
  • At least 7 days after most recent prostate biopsy
  • Imaging evidence of suspected metastatic disease, including CT, bone scan, MRI, ultrasound or other PET modalities (Sub-study #3 only)

Exclusion Criteria:

  • Prior pelvic external beam radiation therapy or brachytherapy
  • Chemotherapy for prostate cancer
  • Hormone deprivation therapy
  • Investigational therapy for prostate cancer
  • Unable to lie flat during or tolerate PET/CT
  • Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.
  • No prostatectomy scheduled more than 12 hours post imaging
  • Serum creatinine > 2 time the upper limit of normal
  • Total bilirubin > 3 times the upper limit of normal
  • Liver Transaminases > 5 times the upper limit of normal
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Gemma Gliori (608) 262-7269 ggliori@uwhealth.org
Contact: Suzanne Hanson (608) 263-7421 shanson@uwhealth.org
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03232164
Other Study ID Numbers  ICMJE UW16062
P30CA014520 ( U.S. NIH Grant/Contract )
2016-0883 ( Other Identifier: Institutional Review Board )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Wisconsin, Madison
Study Sponsor  ICMJE University of Wisconsin, Madison
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: Steve Y Cho, MD University of Wisconsin, Madison
PRS Account University of Wisconsin, Madison
Verification Date August 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP